Evofem Biosciences Reports $5.5M Net Loss in Q1, Reversing Prior Year's Profit
EVFM has more than doubled off its 52-week low of $0.001.
Summary
Evofem Biosciences reported a net loss of $(5.485M) and diluted EPS of $(0.04) for Q1 2026, a significant deterioration from a net income of $953K in the prior-year quarter, despite a modest 6.4% year-over-year revenue increase to $899K. This substantial swing to a loss further exacerbates the company's already precarious financial position, which was highlighted by a going concern warning, critical liquidity issues, and debt defaults in its last 10-K filing. For a company with such severe financial distress, the inability to achieve profitability and the deepening losses are highly material, casting further doubt on its long-term viability. Traders will be closely watching for any updates on financing, cash burn, and the company's ability to address its going concern status.
At the time of this announcement, EVFM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $888K. The 52-week trading range was $0.00 to $0.02. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.